Business
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates
Multiple catalysts for potentially transformative assets in second half of 2024Strong momentum expected from positive topline results of Phase 3 Mino-Lok®
About this update from Citius Oncology, Inc.
[{"type":"text","content":"Multiple catalysts for potentially transformative assets in second half of 2024Strong momentum expected from positive topline results of Phase 3 Mino-Lok® trial, commercialization of LYMPHIR™ if approvedFirst-and-only advantage for Mino-Lok with no current FDA-approved or investigational products; LYMPHIR expected to be additive to current treatment options with mechanism of action supporting market advantageFinancial platform and pending oncology spin-off support pipeline development and investment in long-term growthClinical and operational achievements offer powerful levers for value creationNational Sales Director onboarded to recruit and lead the sales organization in preparation for anticipated launch of LYMPHIRCRANFORD, N.J., July 10, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (\"Citius\" or the \"Company\") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced expected milestones in the second half of calendar 2024 and recapped key achievements year-to-date\nLeonard Mazur, Chairman and CEO of Citius stated, \"Our solid execution since the beginning of the year sets us up for potentially transformative catalysts in the coming months. Mino-Lok's strong Phase 3 topline results support its potential to become part of the standard of care for treating catheter-related bloodstream infections. Mino-Lok would also have a first and only advantage in a market with no approved or investigational products for salvaging infected central venous catheters. For LYMPHIR™, the FDA is currently reviewing our Biologics License Application, with an expected decision on August 13th. We are preparing for near-term commercialization of LYMPHIR if approved. These near-term catalysts should enable the company to optimize its current cash runway, future cash needs, as well as create potential non-dilutive cash opportunities.\n\"Our primary purpose and mission for these late-stage assets is to provide best-in-class, highly effective treatment options for patients and caregivers,\" Mazur added. \"Ultimately, we believe our achievements and milestones offer powerful levers for value creation.\" \nLate-Stage Assets: Mino-Lok® and LYMPHIR™\nCitius significantly advanced its two late-stage product candidates in the first six months of 202...